RESEARCH
LCS102 Formula
Studied for innate immune activation and chemotherapy compatibility
Research Overview
LCS102 is LifeBiotic’s proprietary botanical formula developed to support innate immune activity in oncology-related settings.
The research behind LCS102 focused on two key questions: whether the formula can activate important innate immune cells, and whether it remains compatible with the cytotoxic activity of conventional chemotherapy agents.
In a peer-reviewed study published in Biomedical Reports, LCS102 was evaluated using human blood samples and preclinical cancer cell-line models. The study examined neutrophil activation, natural killer cell activation, cancer cell-line response, and interaction with chemotherapy agents including doxorubicin, Taxol, etoposide, and cisplatin.
Research Areas
Support during chemotherapy
LCS102 was evaluated for its effect on innate immunity, the body’s first line of immune defense.
Human blood samples were exposed to LCS102 and analyzed for immune-cell activation. The study reported increased activation of key innate immune cells, including neutrophils and natural killer cells.
Published in: Biomedical Reports
Study type: Human blood sample immune activity study
Main focus: Innate immune activation
Finding highlighted: LCS102 increased activation of neutrophils and natural killer cells in the samples tested.
Natural Killer Cell Activation
Natural killer cells are part of the innate immune system and play an important role in immune surveillance.
The LCS102 study evaluated natural killer cell activation after human blood samples were exposed to the formula. The results showed increased NK cell activation in the tested samples, with variability between individual donors.
Published in: Biomedical Reports
Study type: Human blood sample immune activity study
Main focus: NK cell activation
Finding highlighted: LCS102 increased natural killer cell activation in the tested blood samples.
Neutrophil Activation
Neutrophils are a central component of innate immunity and are especially relevant in oncology settings, where chemotherapy may suppress immune function.
The study examined neutrophil activation in human blood samples following exposure to LCS102. The findings showed increased activation of neutrophils in the majority of samples tested.
Published in: Biomedical Reports
Study type: Human blood sample immune activity study
Main focus: Neutrophil activation
Finding highlighted: LCS102 increased neutrophil activation in the blood samples tested.
Chemotherapy Compatibility
A central safety question for botanical formulas used in oncology-related settings is whether they may interfere with the anti-cancer activity of chemotherapy.
LCS102 was tested together with several chemotherapy agents, including doxorubicin, Taxol, etoposide, and cisplatin, across human cancer cell-line models. The study reported that LCS102 did not inhibit the cytotoxic effects of the chemotherapy agents tested. In certain models, the addition of LCS102 increased anti-cancer activity.
Published in: Biomedical Reports
Study type: Preclinical chemotherapy interaction study
Main focus: Chemotherapy compatibility
Finding highlighted: LCS102 did not inhibit the cytotoxic effects of the chemotherapy agents tested.
Why This Research Matters
Patients undergoing cancer treatment may experience immune suppression, including reduced activity of key innate immune cells such as neutrophils and natural killer cells.
LCS102 was studied in this context to evaluate whether a botanical formula could support innate immune activation while remaining compatible with conventional chemotherapy activity.
The published findings position LCS102 as LifeBiotic’s immune-focused botanical formula, with research showing activation of neutrophils and natural killer cells in human blood samples, together with no inhibition of chemotherapy cytotoxicity in the preclinical models tested.
Educational Notice
This page is intended as an educational resource on LCS102 and the scientific research conducted on the formula.
LCS102 is not intended to replace conventional oncology treatment. Patients undergoing chemotherapy, immunotherapy, radiation therapy, or any cancer treatment should consult their oncologist or qualified healthcare provider before using any supportive-care product.